Brief: Cleo Diagnostics Says Partnership With Entityrisk
18/08/2025 02:30
Aug 18 (Reuters) - Cleo Diagnostics Ltd COV.AX: PARTNERSHIP WITH ENTITYRISK TO PROVIDE EVIDENCE-BASED INSIGHT INTO ECONOMIC VALUE OF CO'S OVARIAN CANCER PRE-SURGICAL TEST IN U.S. Further company coverage: COV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CLEO Diagnostics
See all newsBrief: Cleo Diagnostics Raises A$5M
Brief: Cleo Diagnostics Seeks Trading Halt Pending Material Capital Raising Announcement
Brief: Cleo Diagnostics Says Partnership With Entityrisk
Australia's Cleo Diagnostics rises to near 2-month high on US approval for trial
Australia's Cleo Diagnostics jumps on US clinical trials for cancer blood test